Document is current
Any future updates will be listed below
-
Authors
Veverová, Kateřina https://orcid.org/0000-0002-5845-1854
Katonová, Alžběta
Horáková, Hana
Laczó, Jan
Angelucci, Francesco
Hort, Jakub
Lautrup, Sofie
Fang, Evandro Fei
Vyhnálek, Martin https://orcid.org/0000-0002-5976-4932
-
Funding
Funding for this research was provided by:
KAPPA programme (TO01000215)
National Institute for Neurological Research (LX22NPO5107)
Institutional Support of Excellence (6980382)
- License Information
-
More Information
Article History
Received: 20 June 2024
Accepted: 8 January 2025
First Online: 20 February 2025
Declarations
:
: All study participants signed an informed consent form approved by the Motol University Hospital ethics committee (number EK218/20).
: All authors have approved the manuscript and agree with its submission.
: E.F.F. has an MTA with LMITO Therapeutics Inc (South Korea), a CRADA arrangement with ChromaDex (USA), and a commercialization agreement with Molecule AG/VITADAO, and is a consultant to Aladdin Healthcare Technologies (UK and Germany), the Vancouver Dementia Prevention Centre (Canada), Intellectual Labs (Norway), MindRank AI (China), and NYO3 (China). J.H. is a medical advisor at Neurona lab, Terrapino mobile app, consulted for Eisai, Eli Lilly, Biogen, Schwabe, holds stock options in Alzheon. K.V., J.L., A.K., H.H., V.M., F.A., M.L., Z.N., H.-L.W., J.Z., L.S., and M.V. have nothing to disclose.
